0	10	Expression	expression	NN
11	14	and	and	CC
15	22	genomic	genomic	JJ
23	36	configuration	configuration	NN
37	39	of	of	IN
40	46	GM-CSF	GM-CSF	NNP
46	47	,	,	,
48	52	IL-3	IL-3	NNP
52	53	,	,	,
54	59	M-CSF	M-CSF	NNP
60	68	receptor	receptor	NN
69	70	(	(	(
70	75	C-FMS	C-FMS	NNP
75	76	)	)	)
76	77	,	,	,
78	83	early	early	JJ
84	90	growth	growth	NN
91	99	response	response	NN
100	106	gene-1	gene-1	NN
107	108	(	(	(
108	113	EGR-1	egr-1	NN
113	114	)	)	)
115	118	and	and	CC
119	124	M-CSF	M-CSF	NNP
125	130	genes	gene	NNS
131	133	in	in	IN
134	141	primary	primary	JJ
142	157	myelodysplastic	myelodysplastic	JJ
158	167	syndromes	syndrome	NNS
167	168	.	.	.

170	180	Peripheral	peripheral	JJ
181	186	blood	blood	NN
187	198	mononuclear	mononuclear	JJ
199	204	cells	cell	NNS
205	209	from	from	IN
210	219	seventeen	seventeen	CD
220	228	patients	patient	NNS
229	233	with	with	IN
234	241	primary	primary	JJ
242	257	myelodysplastic	myelodysplastic	JJ
258	267	syndromes	syndrome	NNS
268	269	(	(	(
269	272	MDS	MDS	NNP
272	273	)	)	)
274	276	in	in	IN
277	285	advanced	advance	VBN
286	291	stage	stage	NN
292	296	were	be	VBD
297	305	enriched	enrich	VBN
306	309	for	for	IN
310	316	blasts	blast	NNS
317	320	and	and	CC
321	327	tested	test	VBN
328	331	for	for	IN
332	333	(	(	(
333	334	1	1	LS
334	335	)	)	)
336	345	karyotype	karyotype	NN
345	346	,	,	,
347	348	(	(	(
348	349	2	2	LS
349	350	)	)	)
351	358	genomic	genomic	JJ
359	372	configuration	configuration	NN
373	376	and	and	CC
377	378	(	(	(
378	379	3	3	LS
379	380	)	)	)
381	391	expression	expression	NN
392	394	of	of	IN
395	399	IL-3	IL-3	NNP
399	400	,	,	,
401	407	GM-CSF	GM-CSF	NNP
407	408	,	,	,
409	412	FMS	FMS	NNP
413	416	and	and	CC
417	422	EGR-1	egr-1	NN
423	428	genes	gene	NNS
429	434	which	which	WDT
435	438	are	be	VBP
439	442	all	all	DT
443	450	located	located	JJ
451	453	on	on	IN
454	457	the	the	DT
458	462	long	long	JJ
463	466	arm	arm	NN
467	469	of	of	IN
470	480	chromosome	chromosome	NN
481	482	5	5	CD
482	483	.	.	.

484	487	The	the	DT
488	498	expression	expression	NN
499	501	of	of	IN
502	505	the	the	DT
506	511	M-CSF	M-CSF	NNP
512	516	gene	gene	NN
516	517	,	,	,
518	522	that	that	WDT
523	526	has	have	VBZ
527	531	been	be	VBN
532	540	recently	recently	RB
541	551	reassigned	reassign	VBN
552	554	to	to	TO
555	558	the	the	DT
559	564	short	short	JJ
565	568	arm	arm	NN
569	571	of	of	IN
572	582	chromosome	chromosome	NN
583	584	1	1	CD
585	586	(	(	(
586	588	lp	lp	NN
588	589	)	)	)
589	590	,	,	,
591	594	was	be	VBD
595	599	also	also	RB
600	613	investigated.	investigated.	VBN
614	618	Aims	aim	NNS
619	621	of	of	IN
622	625	the	the	DT
626	631	study	study	NN
632	636	were	be	VBD
637	639	to	to	TO
640	641	(	(	(
641	642	1	1	CD
642	643	)	)	)
644	650	assess	assess	VBP
651	654	the	the	DT
655	664	potential	potential	JJ
665	669	role	role	NN
670	672	of	of	IN
673	676	the	the	DT
677	687	expression	expression	NN
688	690	of	of	IN
691	696	these	these	DT
697	702	genes	gene	NNS
703	705	in	in	IN
706	709	the	the	DT
710	721	maintenance	maintenance	NN
722	725	and	and	CC
726	735	expansion	expansion	NN
736	738	of	of	IN
739	742	the	the	DT
743	753	neoplastic	neoplastic	JJ
754	760	clones	clone	NNS
761	764	and	and	CC
765	766	(	(	(
766	767	2	2	LS
767	768	)	)	)
769	775	search	search	NN
776	779	for	for	IN
780	794	constitutional	constitutional	JJ
795	801	losses	loss	NNS
802	804	or	or	CC
805	819	rearrangements	rearrangement	NNS
820	822	of	of	IN
823	826	one	one	CD
827	833	allele	allele	NN
834	842	followed	follow	VBN
843	845	by	by	IN
846	847	a	a	DT
848	856	deletion	deletion	NN
857	859	of	of	IN
860	863	the	the	DT
864	870	second	second	JJ
871	877	allele	allele	NN
878	880	of	of	IN
881	884	the	the	DT
885	889	same	same	JJ
890	895	genes	gene	NNS
896	898	in	in	IN
899	902	the	the	DT
903	911	leukemic	leukemic	JJ
912	917	cells	cell	NNS
917	918	.	.	.

919	922	The	the	DT
923	929	latter	latter	JJ
930	935	issue	issue	NN
936	939	was	be	VBD
940	952	investigated	investigate	VBN
953	955	by	by	IN
956	965	comparing	compare	VBG
965	966	,	,	,
967	969	in	in	IN
970	971	8	8	CD
972	977	cases	case	NNS
977	978	,	,	,
979	991	constitutive	constitutive	JJ
992	995	DNA	dna	NN
996	1000	from	from	IN
1001	1005	skin	skin	NN
1006	1017	fibroblasts	fibroblast	NNS
1018	1022	with	with	IN
1023	1031	leukemic	leukemic	JJ
1032	1035	DNA	dna	NN
1035	1036	.	.	.

1037	1043	Eleven	eleven	CD
1044	1046	of	of	IN
1047	1050	the	the	DT
1051	1053	17	17	CD
1054	1062	patients	patient	NNS
1063	1066	had	have	VBD
1067	1075	abnormal	abnormal	JJ
1076	1086	karyotypes	karyotype	NNS
1086	1087	.	.	.

1088	1091	The	the	DT
1092	1097	M-CSF	M-CSF	NNP
1098	1102	gene	gene	NN
1103	1106	was	be	VBD
1107	1116	expressed	express	VBN
1117	1119	in	in	IN
1120	1121	6	6	CD
1122	1127	cases	case	NNS
1128	1131	and	and	CC
1132	1135	the	the	DT
1136	1139	FMS	FMS	NNP
1140	1143	and	and	CC
1144	1147	the	the	DT
1148	1153	EGR-1	egr-1	NN
1154	1159	genes	gene	NNS
1160	1164	were	be	VBD
1165	1174	expressed	express	VBN
1175	1177	in	in	IN
1178	1179	2	2	CD
1180	1182	of	of	IN
1183	1186	the	the	DT
1187	1193	latter	latter	JJ
1194	1199	cases	case	NNS
1199	1200	.	.	.

1201	1203	An	an	DT
1204	1213	autocrine	autocrine	JJ
1214	1223	mechanism	mechanism	NN
1224	1226	of	of	IN
1227	1233	growth	growth	NN
1234	1239	could	could	MD
1240	1242	be	be	VB
1243	1255	hypothesized	hypothesize	VBN
1256	1260	only	only	RB
1261	1264	for	for	IN
1265	1268	the	the	DT
1269	1270	2	2	CD
1271	1279	patients	patient	NNS
1280	1285	whose	whose	WP$
1286	1291	cells	cell	NNS
1292	1301	expressed	express	VBD
1302	1306	both	both	CC
1307	1310	the	the	DT
1311	1316	M-CSF	M-CSF	NNP
1317	1320	and	and	CC
1321	1324	FMS	FMS	NNP
1325	1330	genes	gene	NNS
1330	1331	.	.	.

1332	1334	No	no	DT
1335	1343	germline	germline	NN
1344	1351	changes	change	NNS
1352	1354	or	or	CC
1355	1369	rearrangements	rearrangement	NNS
1370	1374	were	be	VBD
1375	1383	observed	observe	VBN
1384	1386	in	in	IN
1387	1390	any	any	DT
1391	1393	of	of	IN
1394	1397	the	the	DT
1398	1403	genes	gene	NNS
1404	1411	studied	study	VBN
1411	1412	.	.	.

1413	1417	Thus	thus	RB
1417	1418	,	,	,
1419	1431	deregulation	deregulation	NN
1432	1434	of	of	IN
1435	1440	genes	gene	NNS
1441	1449	encoding	encode	VBG
1450	1453	for	for	IN
1454	1461	certain	certain	JJ
1462	1473	hemopoietic	hemopoietic	JJ
1474	1480	growth	growth	NN
1481	1488	factors	factor	NNS
1489	1491	or	or	CC
1492	1501	receptors	receptor	NNS
1502	1506	does	do	VBZ
1507	1510	not	not	RB
1511	1515	seem	seem	VB
1516	1518	to	to	TO
1519	1528	represent	represent	VB
1529	1530	a	a	DT
1531	1536	major	major	JJ
1537	1546	mechanism	mechanism	NN
1547	1549	of	of	IN
1550	1553	MDS	MDS	NNP
1554	1565	progression	progression	NN
1565	1566	.	.	.